An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Eribulin (Primary)
Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Gastric cancer; HER2 negative breast cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Sponsors Eisai Co Ltd

05 Nov 2024 Planned End Date changed from 31 Aug 2025 to 31 Mar 2026.
29 Feb 2024 Planned End Date changed from 31 Aug 2024 to 31 Aug 2025.
24 Oct 2023 Results (n=26; At the data cutoff date October 26, 2022) assessing the efficacy and safety data from the dose-expansion part in patients with metastatic/advanced HER2-negative breast cancer, presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com